Protara Therapeutics (TARA) EBITDA (2013 - 2026)

Protara Therapeutics (TARA) has 14 years of EBITDA data on file, last reported at -$19.6 million in Q1 2026.

• On a quarterly basis, EBITDA fell 38.98% year-over-year to -$19.6 million in Q1 2026; TTM through Mar 2026 was -$70.1 million, a 36.22% decrease from a year earlier, with the FY2025 full-year figure at -$64.5 million, down 31.32% from the prior year.
• EBITDA for Q1 2026 stood at -$19.6 million, down from -$19.1 million in the prior quarter.
• Over the last five years, EBITDA for TARA reached as high as -$8.0 million in Q3 2022 and fell as low as -$39.5 million in Q4 2022.
• Historically, EBITDA has averaged -$14.4 million across 5 years, with a median of -$12.1 million in 2023.
• Across the five-year window, EBITDA plunged 284.07% in 2022 and surged 72.05% in 2023, its largest moves.
• Year by year, EBITDA stood at -$39.5 million in 2022, then jumped by 72.05% to -$11.0 million in 2023, then retreated by 29.63% to -$14.3 million in 2024, then tumbled by 33.31% to -$19.1 million in 2025, then slipped by 2.88% to -$19.6 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$19.6 million in Q1 2026, -$19.1 million in Q4 2025, and -$14.8 million in Q3 2025.